• 中国精品科技期刊
  • 《中文核心期刊要目总览》收录期刊
  • RCCSE 中国核心期刊(5/114,A+)
  • Scopus收录期刊
  • 美国《化学文摘》(CA)收录期刊
  • WHO 西太平洋地区医学索引(WPRIM)收录期刊
  • 《中国科学引文数据库(CSCD)》核心库期刊 (C)
  • 中国科技核心期刊
  • 中国科技论文统计源期刊
  • 《日本科学技术振兴机构数据库(中国)》(JSTChina)收录期刊
  • 美国《乌利希期刊指南》(UIrichsweb)收录期刊
  • 中华预防医学会系列杂志优秀期刊(2019年)

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

新型冠状病毒肺炎长期症状及其科学防控

刘巧, 杜敏, 刘珏, 刘民. 新型冠状病毒肺炎长期症状及其科学防控[J]. 中华疾病控制杂志, 2022, 26(7): 745-749. doi: 10.16462/j.cnki.zhjbkz.2022.07.001
引用本文: 刘巧, 杜敏, 刘珏, 刘民. 新型冠状病毒肺炎长期症状及其科学防控[J]. 中华疾病控制杂志, 2022, 26(7): 745-749. doi: 10.16462/j.cnki.zhjbkz.2022.07.001
LIU Qiao, DU Min, LIU Jue, LIU Min. Long COVID-19 and its scientific prevention and control[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(7): 745-749. doi: 10.16462/j.cnki.zhjbkz.2022.07.001
Citation: LIU Qiao, DU Min, LIU Jue, LIU Min. Long COVID-19 and its scientific prevention and control[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(7): 745-749. doi: 10.16462/j.cnki.zhjbkz.2022.07.001

新型冠状病毒肺炎长期症状及其科学防控

doi: 10.16462/j.cnki.zhjbkz.2022.07.001
刘巧和杜敏为共同第一作者
基金项目: 

国家自然科学基金 72122001

国家自然科学基金 71934002

国家重点研发计划 2021ZD0114101

国家重点研发计划 2021ZD0114104

国家重点研发计划 2021ZD0114105

首都卫生发展科研专项项目 2021-1G-4281

详细信息
    通讯作者:

    刘珏,E-mail: jueliu@bjmu.edu.cn

    刘民,E-mail: liumin@bjmu.edu.cn

  • 中图分类号: R181

Long COVID-19 and its scientific prevention and control

LIU Qiao and DU Min contributed equally to this article
Funds: 

National Natural Science Foundation of China 72122001

National Natural Science Foundation of China 71934002

National Key Research and Development Project of China 2021ZD0114101

National Key Research and Development Project of China 2021ZD0114104

National Key Research and Development Project of China 2021ZD0114105

Capital Health Development Scientific Research Project 2021-1G-4281

More Information
  • 摘要: 国内外已有较多研究发现新型冠状病毒(简称新冠病毒)感染者存在长期症状,即COVID-19长期症状(long COVID-19),也被称为COVID-19后遗症(post-COVID-19 condition)。WHO将COVID-19长期症状定义为新冠病毒感染者在感染病毒3个月后所出现的、持续至少2个月,并且无法被其他诊断所解释的症状。COVID-19长期症状包括全身症状如疲劳、头痛及呼吸困难等,影响精神与神经、呼吸、心血管和消化等多个系统。基于已有研究证据,建议加强COVID-19长期症状的科学研究、现阶段坚持“动态清零”总方针、加快推进疫苗全程接种、未来开展COVID-19长期症状的早期监测与干预,以有效防止COVID-19长期症状带来的远期疾病负担和经济负担。
  • [1] Worldometer. COVID-19 coronavirus pandemic[EB/OL]. (2022-04-22)[2022-04-24]. https://www.worldometers.info/coronavirus/.
    [2] Garg M, Maralakunte M, Garg S, et al. The conundrum of 'Long-COVID-19': a narrative review[J]. Int J Gen Med, 2021, 14: 2491-2506. DOI: 10.2147/ijgm.S316708.
    [3] Cabrera martimbianco AL, Pacheco RL, Bagattini ÂM, et al. Frequency, signs and symptoms, and criteria adopted for long COVID-19: a systematic review[J]. Int J Clin Pract, 2021, 75(10): e14357. DOI: 10.1111/ijcp.14357.
    [4] Yan Z, Yang M, Lai CL. Long COVID-19 syndrome: a comprehensive review of its effect on various organ systems and recommendation on rehabilitation plans[J]. Biomedicines, 2021, 9(8): 966. DOI: 10.3390/biomedicines9080966.
    [5] Soriano JB, Murthy S, Marshall JC, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus[J]. Lancet Infect Dis, 2022, 22(4): e102-e107. DOI: 10.1016/S1473-3099(21)00703-9.
    [6] World Health Organization. Coronavirus disease (COVID-19) science conversation[EB/OL]. (2022-04-13)[2022-04-24]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/science-in-5.
    [7] National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19[M]. London: National Institute for Health and Care Excellence, 2020.
    [8] The Lancet. Facing up to long COVID-19[J]. Lancet, 2020, 396(10266): 1861. DOI: 10.1016/s0140-6736(20)32662-3.
    [9] Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID-19[J]. Nature medicine, 2021, 27(4): 626-631. DOI: 10.1038/s41591-021-01292-y.
    [10] Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China[J]. JAMA Neurol, 2020, 77(6): 683-690. DOI: 10.1001/jamaneurol.2020.1127.
    [11] Douaud G, Lee S, Alfaro-almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank[J]. Nature, 2022, 604(7907): 697-707. DOI: 10.1038/s41586-022-04569-5.
    [12] Lechien JR, Chiesa-estomba CM, De siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study[J]. Eur Arch Otorhinolaryngol, 2020, 277(8): 2251-2261. DOI: 10.1007/s00405-020-05965-1.
    [13] de Melo GD, Lazarini F, Levallois S, et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters[J]. Sci Transl Med, 2021, 13(596): eabf8396. DOI: 10.1126/scitranslmed.abf8396.
    [14] Shelton JF, Shastri AJ, Fletez-brant K, et al. The UGT2A1/UGT2A2 locus is associated with COVID-19-related loss of smell or taste[J]. Nat Genet, 2022, 54(2): 121-124. DOI: 10.1038/s41588-021-00986-w.
    [15] Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records[J]. Lancet Psychiatry, 2021, 8(5): 416-427. DOI: 10.1016/s2215-0366(21)00084-5.
    [16] Magnúsdóttir I, Lovik A, Unnarsdóttir A B, et al. Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study[J]. Lancet Public Health, 2022, 7(5): e406-e416. DOI: 10.1016/s2468-2667(22)00042-1.
    [17] Xie Y, Xu E, Al-aly Z. Risks of mental health outcomes in people with COVID-19: cohort study[J]. BMJ, 2022, 376: e068993. DOI: 10.1136/bmj-2021-068993.
    [18] Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic[J]. Lancet Psychiatry, 2020, 7(7): 611-627. DOI: 10.1016/s2215-0366(20)30203-0.
    [19] Mazza MG, Palladini M, De Lorenzo R, et al. One-year mental health outcomes in a cohort of COVID-19 survivors[J]. J Psychiatr Res, 2021, 145: 118-124. DOI: 10.1016/j.jpsychires.2021.11.031.
    [20] Carfì A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19[J]. JAMA, 2020, 324(6): 603-605. DOI: 10.1001/jama.2020.12603.
    [21] Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study[J]. Clin Microbiol Infect, 2021, 27(1): 89-95. DOI: 10.1016/j.cmi.2020.09.023.
    [22] Wu X, Liu X, Zhou Y, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study[J]. Lancet Respir Med, 2021, 9(7): 747-754. DOI: 10.1016/s2213-2600(21)00174-0.
    [23] Bouteleux B, Henrot P, Ernst R, et al. Respiratory rehabilitation for COVID-19 related persistent dyspnoea: a one-year experience[J]. Respir Med, 2021, 189: 106648. DOI: 10.1016/j.rmed.2021.106648.
    [24] Fumagalli C, Zocchi C, Tassetti L, et al. Factors associated with persistence of symptoms 1 year after COVID-19: a longitudinal, prospective phone-based interview follow-up cohort study[J]. Eur J Intern Med, 2022, 97: 36-41. DOI: 10.1016/j.ejim.2021.11.018.
    [25] Wang Y, Dong C, Hu Y, et al. Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study[J]. Radiology, 2020, 296(2): e55-e64. DOI: 10.1148/radiol.2020200843.
    [26] Garg M, Gupta P, Maralakunte M, et al. Diagnostic accuracy of CT and radiographic findings for novel coronavirus 2019 pneumonia: systematic review and meta-analysis[J]. Clin Imaging, 2021, 72: 75-82. DOI: 10.1016/j.clinimag.2020.11.021.
    [27] Mo X, Jian W, Su Z, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge[J]. Eur Respir J, 2020, 55(6): 2001217. DOI: 10.1183/13993003.01217-2020.
    [28] Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)[J]. JAMA Cardiol, 2020, 5(7): 819-824. DOI: 10.1001/jamacardio.2020.1096.
    [29] Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19[J]. Nat Med, 2022, 28(3): 583-590. DOI: 10.1038/s41591-022-01689-3.
    [30] Huang L, Zhao P, Tang D, et al. Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging[J]. JACC Cardiovasc Imaging, 2020, 13(11): 2330-2339. DOI: 10.1016/j.jcmg.2020.05.004.
    [31] Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)[J]. JAMA Cardiol, 2020, 5(11): 1265-1273. DOI: 10.1001/jamacardio.2020.3557.
    [32] Rajpal S, Tong MS, Borchers J, et al. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection[J]. JAMA Cardiol, 2021, 6(1): 116-118. DOI: 10.1001/jamacardio.2020.4916.
    [33] 石永言. 病例报告和系统综述表明临床诊断新型冠状病毒肺炎后儿童或受到类似成人的长期影响[J]. 国际儿科学杂志, 2021, 48(3): 206. DOI: 10.3760/cma.j.issn.1673-4408.2021.03.103.

    Shi YY. Case report and systematic review indicate the long-term effects of clinically diagnosed new coronavirus pneumonia on children or similar adults[J]. Int J Pediatr, 2021, 48(3): 206. DOI: 10.3760/cma.j.issn.1673-4408.2021.03.103.
    [34] Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after COVID-19: nationwide self-controlled cases series and matched cohort study[J]. BMJ, 2022, 377: e069590. DOI: 10.1136/bmj-2021-069590.
    [35] Kariyawasam JC, Jayarajah U, Riza R, et al. Gastrointestinal manifestations in COVID-19[J]. Trans R Soc Trop Med Hyg, 2021, 115(12): 1362-1388. DOI: 10.1093/trstmh/trab042.
    [36] Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis[J]. Gastroenterology, 2020, 159(1): 81-95. DOI: 10.1053/j.gastro.2020.03.065.
    [37] Penner J, Abdel-Mannan O, Grant K, et al. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study[J]. Lancet Child Adolesc Health, 2021, 45(7): 473-482. DOI: 10.1016/s2352-4642(21)00138-3.
    [38] Wu Y, Guo C, Tang L, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples[J]. Lancet Gastroenterol Hepatol, 2020, 5(5): 434-435. DOI: 10.1016/s2468-1253(20)30083-2.
    [39] McMahon DE, Gallman AE, Hruza GJ, et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration[J]. Lancet Infect Dis, 2021, 21(3): 313-314. DOI: 10.1016/s1473-3099(20)30986-5.
    [40] Suchonwanit P, Leerunyakul K, Kositkuljorn C. Cutaneous manifestations in COVID-19: lessons learned from current evidence[J]. J Am Acad Dermatol, 2020, 83(1): e57-e60. DOI: 10.1016/j.jaad.2020.04.094.
    [41] Wan KH, Lui GCY, Poon KCF, et al. Ocular surface disturbance in patients after acute COVID-19[J]. Clin Exp Ophthalmol, 2022, 10. DOI: 10.1111/ceo.14066.
    [42] Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study[J]. Lancet Diabetes Endocrinol, 2022, 10(5): 311-321. DOI: 10.1016/s2213-8587(22)00044-4.
    [43] Anwar S, Acharya S, Shabih S, et al. Acute Limb Ischemia in COVID-19 Disease: a mysterious coagulopathy[J]. Cureus, 2020, 12(7): e9167. DOI: 10.7759/cureus.9167.
    [44] Acharya S, Anwar S, Siddiqui FS, et al. Renal artery thrombosis in COVID-19[J]. IDCases, 2020, 22: e00968. DOI: 10.1016/j.idcr.2020.e00968.
    [45] Fernandez CE, Franz CK, Ko JH, et al. Imaging review of peripheral nerve injuries in patients with COVID-19[J]. Radiology, 2021, 298(3): e117-e130. DOI: 10.1148/radiol.2020203116.
    [46] 梁万年, 刘民, 刘珏, 等. 我国新型冠状病毒肺炎疫情防控的"动态清零"策略[J]. 中华医学杂志, 2022, 102(4): 239-242. DOI: 10.3760/cma.j.cn112137-20211205-02710.

    Liang WN, Liu M, Liu J, et al. The dynamic COVID-zero strategy on prevention and control of COVID-19 in China[J]. National Med J China. 2022, 102(4): 239-242. DOI: 10.3760/cma.j.cn112137-20211205-02710.
    [47] Heidi L. Can drugs reduce the risk of long COVID? What scientists know so far[J]. Nature, 2022, 604(1): 20-21. DOI: 10.1038/d41586-022-00823-y.
    [48] 吴俣, 刘珏, 刘民, 等. 新型冠状病毒Omicron变异株的流行病学特征及防控研究[J]. 中国全科医学, 2022, 25(1): 14-19. DOI: 10.12114/j.issn.1007-9572.2021.00.348.

    Wu Y, Liu J, Liu M, et al. Epidemiologic features and containment of SARS-CoV-2 omicron variant[J]. Chinese General Practice, 2022, 25(1): 14-19. DOI: 10.12114/j.issn.1007-9572.2021.00.348.
    [49] 杜敏, 刘民, 刘珏. 新型冠状病毒Delta变异株的流行病学特征及防控研究进展[J]. 中华流行病学杂志, 2021, 42(10): 1774-1779. DOI: 10.3760/cma.j.cn112338-20210808-00619.

    Du M, Liu M, Liu J. Progress in research of epidemiologic feature and control of SARS-CoV-2 Delta variant[J]. Chin J Epidemiol, 2021, 42(10): 1774-1779. DOI: 10.3760/cma.j.cn112338-20210808-00619.
    [50] Ayoubkhani D, Bosworth ML, King S, et al. Risk of long COVID in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study[J]. medRxiv, 2022. DOI: 10.1101/2022.02.23.22271388.
  • 加载中
计量
  • 文章访问数:  92
  • HTML全文浏览量:  26
  • PDF下载量:  173
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-04-24
  • 修回日期:  2022-05-11
  • 网络出版日期:  2022-07-19
  • 刊出日期:  2022-07-10

目录

    /

    返回文章
    返回